On October 7, 2025, Chardan Capital set a price target of $17 for Lexeo Therapeutics, Inc. (NASDAQ:LXEO). At the time, the stock was trading at $8.25, suggesting a potential increase of about 94%. Lexeo is a clinical-stage genetic medicine company focused on developing treatments for rare diseases. Its competitors include other biotech firms working on genetic therapies.
Lexeo has made significant progress with the FDA regarding an Accelerated Approval pathway for its treatment, LX2006, targeting Friedreich ataxia cardiomyopathy. The FDA is open to using data from ongoing Phase I/II studies combined with pivotal data to support a Biologics License Application (BLA). This collaboration could expedite the approval process, potentially boosting investor confidence.
Interim clinical data from Lexeo's studies show promising results. Participants with an abnormal left ventricular mass index (LVMI) at baseline experienced an 18% mean reduction in LVMI at six months and a 23% mean reduction at twelve months. These results surpass the FDA-aligned target threshold of a 10% reduction, indicating the treatment's effectiveness.
Additionally, there was a clinically meaningful improvement in the modified Friedreich Ataxia Rating Scale (mFARS), suggesting slowed disease progression and improved function. This progress highlights the potential of LX2006 to become a life-changing therapy for the Friedreich ataxia community, as emphasized by the company's CEO.
Currently, LXEO is trading at $8.34, reflecting a 28.90% increase with a change of $1.87. The stock has fluctuated between $7.88 and $8.88 today. Over the past year, it reached a high of $11.72 and a low of $1.45. Lexeo's market capitalization is approximately $276.86 million, with a trading volume of 9.42 million shares.
